Sarconeos - Biophytis
Alternative Names: 20-hydroxyecdysone - Biophytis; BIO 101; RUVEMBRILatest Information Update: 09 May 2024
At a glance
- Originator Biophytis
- Class Cyclopentanes; Ketones; Obesity therapies; Phenanthrenes; Small molecules
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III SARS-CoV-2 acute respiratory disease
- Phase II Sarcopenia
- Phase I Duchenne muscular dystrophy
- Preclinical Obesity
Most Recent Events
- 29 Apr 2024 Sarconeos - Biophytis is available for licensing as of 29 Apr 2024. www.biophytis.com 9416321
- 18 Apr 2024 Sarconeos is still in preclinical development in Duchenne muscular dystrophy in France (PO, Capsule)
- 18 Apr 2024 Biophytis plans to file an IND application with the US FDA in for Obesity (PO, Capsule) in May 2024